Reminder of Securities Class Action for Aldeyra Therapeutics Investors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy ALDX?
Source: Globenewswire
- Stock Price Collapse: Aldeyra Therapeutics' stock plummeted 70.7% on March 17, 2026, following the FDA's rejection of its drug efficacy, dropping from $4.23 to $1.24 per share, resulting in a single-day loss of $2.99, indicating severe market disappointment over the company's clinical trial results.
- False Statement Allegations: The lawsuit claims that between November 3, 2023, and March 16, 2026, Aldeyra's stock price was artificially inflated by the company's assertions of broad and rapid efficacy, with the FDA's assessment revealing the falsity of these claims, leading to a market reassessment of the stock price.
- Investor Compensation Opportunity: Affected investors can participate in claims without any out-of-pocket costs, as Levi & Korsinsky offers free evaluations to help investors determine their eligibility for recovering per-share losses.
- Lead Plaintiff Deadline: Investors must apply to be lead plaintiffs by May 29, 2026, to represent the entire investor group in the lawsuit, ensuring their rights are effectively protected throughout the case.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALDX
Wall Street analysts forecast ALDX stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.730
Low
9.00
Averages
9.50
High
10.00
Current: 1.730
Low
9.00
Averages
9.50
High
10.00
About ALDX
Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering therapies designed to treat immune-mediated and metabolic diseases. The Company's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aldeyra Therapeutics Faces Class Action Lawsuit
- Class Action Filed: Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has initiated a class action lawsuit against Aldeyra Therapeutics (NASDAQ: ALDX) and certain officers, seeking damages for investors who purchased Aldeyra securities between November 3, 2023, and March 16, 2026.
- Allegations Overview: The complaint alleges that defendants made false and misleading statements during the class period, failing to disclose inconsistencies in the clinical trial results of reproxalap, which rendered any positive findings unreliable and misled investors about the company's business and prospects.
- Investor Participation: Affected investors are encouraged to apply to be lead plaintiffs by May 29, 2026, allowing them to share in any recovery without needing to serve as lead plaintiffs, thus broadening participation in the lawsuit.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman, LLC is well-regarded for representing investors in securities fraud class actions, having recovered hundreds of millions for investors nationwide, emphasizing their commitment to restoring investor capital and ensuring corporate accountability.
See More
Reminder of Class Action for Aldeyra Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics (NASDAQ: ALDX) securities between November 3, 2023, and March 16, 2026, to apply as lead plaintiffs by May 29, 2026, to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors participating in the class action will incur no upfront costs, as attorney fees will be collected through a contingency fee arrangement, significantly reducing the financial risk of engaging in litigation without guaranteed compensation.
- Lawsuit Background: The lawsuit alleges that during the class period, Aldeyra's management made false and misleading statements and failed to disclose inconsistencies in the clinical trial results of its drug candidate reproxalap, leading to investor losses when the truth emerged.
- Law Firm's Advantage: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked number one by ISS Securities Class Action Services in 2017, highlighting its expertise and influence in the field.
See More
Aldeyra Therapeutics Faces Class Action for Securities Fraud
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Aldeyra Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between November 3, 2023, and March 16, 2026, with a deadline to contact the firm by May 29, 2026.
- False Statement Allegations: The complaint alleges that Aldeyra made false and misleading statements regarding its reproxalap drug candidate, with clinical trial results showing inconsistencies, rendering the company's positive claims unreliable and misleading throughout the class period.
- Investor Losses: As the market learned the truth about Aldeyra, investors suffered damages, indicating significant deficiencies in the company's disclosure practices that could adversely affect its stock price and investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations, encouraging affected shareholders to reach out to discuss their rights, demonstrating the firm's commitment to protecting investor interests.
See More
Aldeyra Therapeutics Faces Class Action Lawsuit Over Misleading Clinical Trial Claims
- Stock Price Collapse: Aldeyra Therapeutics (ALDX) experienced a dramatic 70.7% drop in share price, falling $2.99 to close at $1.24 on March 17, 2026, after the FDA rejected its lead drug candidate, resulting in significant losses for investors.
- Lawsuit Context: A class action lawsuit has been filed against Aldeyra for allegedly making materially false and misleading statements in SEC filings between November 3, 2023, and March 16, 2026, claiming that reproxalap demonstrated 'broad-based, rapid-onset activity and consistent safety' without a reasonable basis.
- FDA Response Letter: The FDA's Complete Response Letter issued in March 2026 highlighted a lack of substantial evidence and raised serious concerns regarding the reliability of the clinical trial results, further eroding investor confidence in the company's claims.
- Investor Rights: Investors have until May 29, 2026, to apply as lead plaintiffs in the case to seek compensation, and even those who sold their shares at a loss may still participate based on their purchase dates and documented losses.
See More
Reminder of Aldeyra Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics (NASDAQ: ALDX) securities between November 3, 2023, and March 16, 2026, that the deadline to apply as lead plaintiff is May 29, 2026, allowing potential compensation without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Aldeyra made false and misleading statements regarding the inconsistent results of its drug candidate reproxalap clinical trials, which misrepresented the company's business and prospects, leading to investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its strong reputation in this legal domain.
- How to Participate: Investors can join the class action by visiting the Rosen Law Firm website or calling toll-free at 866-767-3653 for more information, and those wishing to serve as lead plaintiff must file with the court by the deadline.
See More
Aldeyra Faces Class Action Lawsuit, Stock Plummets
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Aldeyra Therapeutics, alleging securities fraud by the company and certain officers, with investors needing to apply as Lead Plaintiff by May 29, 2026, highlighting serious concerns regarding corporate governance and compliance.
- FDA Response Letter: On March 17, 2026, Aldeyra received a Complete Response Letter from the FDA indicating that its New Drug Application lacked sufficient evidence to demonstrate efficacy for treating dry eye disease, reflecting significant flaws in the drug development process that could impact future product approvals.
- Stock Price Collapse: Following the FDA's negative feedback, Aldeyra's stock plummeted by $2.99, or 70.69%, closing at $1.24 on March 17, 2026, indicating a pessimistic market outlook on the company's future prospects.
- Severe Legal Consequences: The class action lawsuit and the FDA's response letter could expose Aldeyra to substantial damages and reputational harm, exacerbating investor concerns about its future business viability and financial health.
See More
Aldeyra Therapeutics Faces Class Action Lawsuit
- Class Action Filed: Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has initiated a class action lawsuit against Aldeyra Therapeutics (NASDAQ: ALDX) and certain officers, seeking damages for investors who purchased Aldeyra securities between November 3, 2023, and March 16, 2026.
- Allegations Overview: The complaint alleges that defendants made false and misleading statements during the class period, failing to disclose inconsistencies in the clinical trial results of reproxalap, which rendered any positive findings unreliable and misled investors about the company's business and prospects.
- Investor Participation: Affected investors are encouraged to apply to be lead plaintiffs by May 29, 2026, allowing them to share in any recovery without needing to serve as lead plaintiffs, thus broadening participation in the lawsuit.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman, LLC is well-regarded for representing investors in securities fraud class actions, having recovered hundreds of millions for investors nationwide, emphasizing their commitment to restoring investor capital and ensuring corporate accountability.
See More
Reminder of Class Action for Aldeyra Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics (NASDAQ: ALDX) securities between November 3, 2023, and March 16, 2026, to apply as lead plaintiffs by May 29, 2026, to represent other investors in the class action lawsuit.
- Fee Arrangement: Investors participating in the class action will incur no upfront costs, as attorney fees will be collected through a contingency fee arrangement, significantly reducing the financial risk of engaging in litigation without guaranteed compensation.
- Lawsuit Background: The lawsuit alleges that during the class period, Aldeyra's management made false and misleading statements and failed to disclose inconsistencies in the clinical trial results of its drug candidate reproxalap, leading to investor losses when the truth emerged.
- Law Firm's Advantage: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked number one by ISS Securities Class Action Services in 2017, highlighting its expertise and influence in the field.
See More
Aldeyra Therapeutics Faces Class Action for Securities Fraud
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Aldeyra Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between November 3, 2023, and March 16, 2026, with a deadline to contact the firm by May 29, 2026.
- False Statement Allegations: The complaint alleges that Aldeyra made false and misleading statements regarding its reproxalap drug candidate, with clinical trial results showing inconsistencies, rendering the company's positive claims unreliable and misleading throughout the class period.
- Investor Losses: As the market learned the truth about Aldeyra, investors suffered damages, indicating significant deficiencies in the company's disclosure practices that could adversely affect its stock price and investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations, encouraging affected shareholders to reach out to discuss their rights, demonstrating the firm's commitment to protecting investor interests.
See More
Aldeyra Therapeutics Faces Class Action Lawsuit Over Misleading Clinical Trial Claims
- Stock Price Collapse: Aldeyra Therapeutics (ALDX) experienced a dramatic 70.7% drop in share price, falling $2.99 to close at $1.24 on March 17, 2026, after the FDA rejected its lead drug candidate, resulting in significant losses for investors.
- Lawsuit Context: A class action lawsuit has been filed against Aldeyra for allegedly making materially false and misleading statements in SEC filings between November 3, 2023, and March 16, 2026, claiming that reproxalap demonstrated 'broad-based, rapid-onset activity and consistent safety' without a reasonable basis.
- FDA Response Letter: The FDA's Complete Response Letter issued in March 2026 highlighted a lack of substantial evidence and raised serious concerns regarding the reliability of the clinical trial results, further eroding investor confidence in the company's claims.
- Investor Rights: Investors have until May 29, 2026, to apply as lead plaintiffs in the case to seek compensation, and even those who sold their shares at a loss may still participate based on their purchase dates and documented losses.
See More
Reminder of Aldeyra Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics (NASDAQ: ALDX) securities between November 3, 2023, and March 16, 2026, that the deadline to apply as lead plaintiff is May 29, 2026, allowing potential compensation without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Aldeyra made false and misleading statements regarding the inconsistent results of its drug candidate reproxalap clinical trials, which misrepresented the company's business and prospects, leading to investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its strong reputation in this legal domain.
- How to Participate: Investors can join the class action by visiting the Rosen Law Firm website or calling toll-free at 866-767-3653 for more information, and those wishing to serve as lead plaintiff must file with the court by the deadline.
See More
Aldeyra Faces Class Action Lawsuit, Stock Plummets
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Aldeyra Therapeutics, alleging securities fraud by the company and certain officers, with investors needing to apply as Lead Plaintiff by May 29, 2026, highlighting serious concerns regarding corporate governance and compliance.
- FDA Response Letter: On March 17, 2026, Aldeyra received a Complete Response Letter from the FDA indicating that its New Drug Application lacked sufficient evidence to demonstrate efficacy for treating dry eye disease, reflecting significant flaws in the drug development process that could impact future product approvals.
- Stock Price Collapse: Following the FDA's negative feedback, Aldeyra's stock plummeted by $2.99, or 70.69%, closing at $1.24 on March 17, 2026, indicating a pessimistic market outlook on the company's future prospects.
- Severe Legal Consequences: The class action lawsuit and the FDA's response letter could expose Aldeyra to substantial damages and reputational harm, exacerbating investor concerns about its future business viability and financial health.
See More
